CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 12, 2013
Result type: Reports
Project Number: SR0342-000
Product Line: Reimbursement Review

Generic Name: Eplerenone

Brand Name: Inspra

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Heart failure, NYHA class II

Indications: Heart failure, NYHA class II

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 24, 2014

Recommendation Type: Do not list at the submitted price